RaphaRAD develops radiation therapy equipment utilizing intensity-modulated brachytherapy and proton minibeam therapy technologies to deliver targeted cancer treatment while minimizing radiation exposure to surrounding healthy tissues. Their solutions address the challenge of reducing radiation side effects, enabling more effective and safer oncology treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional radiation therapy techniques can damage healthy tissues surrounding tumors, leading to significant side effects and limiting the radiation dose that can be safely delivered to the cancerous tissue. This can compromise treatment efficacy, especially in sensitive areas or for deep-seated tumors.
Solution
RaphaRAD develops advanced radiation therapy solutions designed to minimize damage to healthy tissues while maximizing the dose delivered to tumors. Their core technologies include Intensity-Modulated Brachytherapy (IMBT) and Proton Minibeam Therapy (PMBT). IMBT allows for precise shaping of the radiation dose to conform to the tumor, while PMBT utilizes multiple narrow proton beams to spare healthy tissue between the beams. They also offer quality assurance (QA) solutions for linear accelerators (Linacs) and brachytherapy, as well as a lens shield for electron therapy to protect the eye.
Target Audience
RaphaRAD's primary customers are radiation oncologists, medical physicists, and hospitals or cancer centers utilizing radiation therapy for cancer treatment.
Features
- Intensity-Modulated Brachytherapy (IMBT) for targeted radiation delivery, reducing exposure to surrounding healthy tissues.
- Proton Minibeam Therapy (PMBT) utilizing multiple narrow proton beams to minimize damage to healthy tissue.
- Linac QA solution for quality assurance of linear accelerators.
- Brachytherapy QA solution for quality assurance of brachytherapy treatments.
- Lens Shield for Electron Therapy to protect the eye during electron therapy.